SCHEMBL23927019

SCHEMBL23927019

COc1ccc(CNc2cncnc2Nc2ccc(Oc3ccc(C)c(OC)c3)nc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 3/20 0.42
MAPT P10636 5/20 0.42
LMNA P02545 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP1A2 P05177 6/20 0.40
CYP3A4 P08684 6/20 0.40
CYP2D6 P10635 5/20 0.40
TSHR P16473 5/20 0.40
CYP2C19 P33261 5/20 0.40
HSD17B10 Q99714 3/20 0.40
ALOX15 P16050 2/20 0.40
ALDH1A1 P00352 3/20 0.39
CYP2C9 P11712 2/20 0.39
MAPK1 P28482 1/20 0.39
PDE5A O76074 1/20 0.39
EGFR P00533 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30079787 1.00 PIK3CA (0.42) PIK3CAMAPTLMNANPC1RAB9A
SCHEMBL30079725 0.81 PIK3CA (0.46) PIK3CALMNAMEN1KMT2ACYP1A2
SCHEMBL30079817 0.81 PIK3CG (0.41) PIK3CALMNAMEN1KMT2ACYP1A2
SCHEMBL23926977 0.81 PIK3CG (0.41) PIK3CALMNAMEN1KMT2ACYP1A2
SCHEMBL23927082 0.81 PIK3CA (0.46) PIK3CALMNAMEN1KMT2ACYP1A2
SCHEMBL23927074 0.72 PIK3CA (0.43) PIK3CAMAPTRAB9AMEN1KMT2A
SCHEMBL30079642 0.72 PIK3CA (0.43) PIK3CAMAPTRAB9AMEN1KMT2A
SCHEMBL23926990 0.72 PIK3CA (0.48) PIK3CAMEN1KMT2AHSD17B10ALDH1A1
SCHEMBL30079796 0.72 PIK3CA (0.48) PIK3CAMEN1KMT2AHSD17B10ALDH1A1
SCHEMBL23926951 0.70 MAPT (0.49) PIK3CAMAPTRAB9AL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS HOFFMANN-LA ROCHE INC. (US) 2023-04-20 US disclosed
EP-4139306-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2023-03-01 EP disclosed
CN-115380032-A KV3 enhancers for the treatment of cognitive disorders 豪夫迈·罗氏有限公司 2022-11-22 CN disclosed
WO-2021214090-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2021-10-28 WO disclosed
EP-3901152-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2021-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230124087-A1 KV3 ENHANCERS FOR THE TREATMENT OF COGNITIVE DISORDERS KCNN3, KCNA4, KCNA3 PIK3CA 2780/4885MAPT 1023/4885LMNA 2149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.